Vanguard Group
SNTI icon

Vanguard Group’s Senti Biosciences Holdings SNTI Stock Holding History

Vanguard Group’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$654K Buy
628,697
+12,624
+2% +$22.3K ﹤0.01% 3884
2025
Q3 		$869K Buy
616,073
+255,162
+71% +$426K ﹤0.01% 3823
2025
Q2 		$762K Buy
360,911
+206,775
+134% +$655K ﹤0.01% 3822
2025
Q1 		$518K Buy
154,136
+56,669
+58% +$221K ﹤0.01% 3878
2024
Q4 		$342K Hold
97,467
– – ﹤0.01% 4029
2024
Q3 		$220K Buy
97,467
+26,762
+38% +$70.7K ﹤0.01% 4123
2024
Q2 		$195K Hold
70,705
– – ﹤0.01% 4173
2024
Q1 		$267K Hold
70,705
– – ﹤0.01% 4130
2023
Q4 		$467K Buy
70,705
+15,390
+28% +$60K ﹤0.01% 4053
2023
Q3 		$228K Hold
55,315
– – ﹤0.01% 4232
2023
Q2 		$347K Buy
55,315
+3,772
+7% +$36.8K ﹤0.01% 4210
2023
Q1 		$608K Hold
51,543
– – ﹤0.01% 4065
2022
Q4 		$727K Buy
+51,543
New +$1.26M ﹤0.01% 4003

Other funds holding SNTI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
MG
MSOP GP Menlo Park, California $439M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group's SNTI Position: Q4 2025 in Review

Vanguard Group increased its Senti Biosciences Holdings (SNTI) stake by 2% in Q4 2025, buying an estimated $22.3K and bringing the position to 628,697 shares worth $654K. The position accounts for ﹤0.01% of the portfolio, ranked #3884.

Vanguard Group first reported a position in SNTI in Q4 2022 and has held it in 13 quarters since. The position peaked at $869K in Q3 2025. 15 funds tracked by Wall St. Rank hold SNTI as of Q4 2025.

  • Vanguard Group held 628,697 shares of Senti Biosciences Holdings worth $654K as of Q4 2025.
  • Vanguard Group bought 12,624 Senti Biosciences Holdings shares in Q4 2025, an estimated $22.3K.
  • Senti Biosciences Holdings made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3884 holding.
  • Vanguard Group first reported a position in Senti Biosciences Holdings in Q4 2022 and has held it in 13 quarters since.
  • Vanguard Group's Senti Biosciences Holdings position peaked at $869K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.